Loading the player
Kite PharmaGuest Speakers
Arie Belldegrun MD, FACS . Chairman, President & CEO
Cynthia Butitta . COO & CFO
David Chang MD, PhD . EVP of R&D, CMO
Our goal is to be a leader in immunotherapy in multiple cancer indications. To achieve this, we are developing a pipeline of product candidates for the treatment of advanced solid and hematological malignancies using our therapeutic platform . engineered Autologous Cell Therapy (eACT.) . in which a patient.s own T cells, or white blood cells, are engineered to recognize and destroy their cancer. The patient.s immune system, particularly T cells, plays a critical role in identifying and killing cancer cells. Our eACT. technology involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs), or T cell receptors (TCRs). Our technology has been developed in part through our collaboration with the National Cancer Institute, Surgery Branch through a cooperative research and development agreement (CRADA).
Kite Pharma is advancing a pipeline of proprietary eACT -based product candidates to create personalized therapies targeting a broad range of indications in cancer.
ABOUT THE SERIES:
CNSI's Entrepreneurship Forum is designed to enable entrepreneurial UCLA faculty, staff and students to exchange ideas and build relationships within the LA entrepreneurial ecosystem. The forum serves CNSI's mission to facilitate commercialization by creating an environment where innovative ideas can be shared and cultivated into commercial opportunities.